Osteoarthritis Quo Vadis

Interest in OA from investigators, governmental agencies, nonprofit institutions, and pharmaceutical companies is at an all-time high—an appropriate response to the ever-increasing burden we can expect in the aging baby-boomer population over the next decade. I am hopeful that, down the line, when Dr. Pisetsky asks me to write an update on OA treatment, we will have found “Dr. Ehrlich’s Magic Bullet” for OA.

Dr. Moskowitz is professor of medicine at Case Western Reserve University and director of the Rheumatology Clinical Research Center at University Hospitals, both in Cleveland. The editorial assistance of Ann Awadalla, rheumatology clinical research center student intern, is appreciated.

References

1. Felson DT, Kim YJ. The futility of current approaches to chondroprotection. Arthritis Rheum. 2007;56(5):1378-1383.
2. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets [review]. Arthritis Rheum. 2001;44:1237-1247.
3. Moskowitz RW, Altman, RD, Hochberg, M, Buckwalter, J, Goldberg, VM. Osteoarthritis—Diagnosis and Management. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
4. Abramson SB, Honig S. Antiresorptive agents and osteoarthritis: More than a bone to pick? Arthritis Rheum. 2007;56:2469-2473.
5. Holderbaum D, Haqqi TM, Moskowitz RW. Genetics of osteoarthritis: Exposing the iceberg. Arthritis Rheum. 1999;42:397-405.
6. ACR Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000; 43:1905-1915.
7. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137-162.
8. Moskowitz RW, Abramson SB, Berenbaum F, Simon LS, Hochberg M. COXibs and NSAIDS—Is the air any clearer? Perspectives from the OARSI international COX-2 workshop 2007. Osteoarthritis Cartilage. 2007;15(8):849-856.
9. Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: Selectivity is with the patient, not the drug class. Ann Rheum Dis. 2005;64:S85-S86.
10. Antman EM, Bennet JS, Daughtery A, et al. Use of nonsteroidal anti-inflammatory drugs: An update for clinicians. Circulation. 2007;115:1634-1642.
11. Altman RD, Moskowitz RW. Hyaluronate sodium injections for osteoarthritis. Arch Intern Med. 2002;162:2498-2499; author reply 2499-2500.
12. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effect of glucosamine sulfate on osteoarthritis progression: a randomized placebo-controlled clinical trial. Lancet. 2001;27:251-265.
13. McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283:1469-1475.
14. Leeb BF, Schweitzer H, Montag K, et al. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2002;27:205-222.
15. Clegg D, Reda D, Harris H, et al. Efficacy of glucosamine, chondroitin sulfate, and the combination in painful knee osteoarthritis. N Eng J Med. 2006;354:797-808.
16. Moskowitz RW, Hooper M. State-of-the-art disease-modifying osteoarthritis drugs. Curr Rheumatol Rep. 2005;7:15-21.
17. Peterfy CG, Guermazi MD, Zaim MD, et al. Whole-organ magnetic resonance imaging score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage. 2004; 12:177-190.
18. Brandt KD, Mazucca SA, Conrozier T, et al. What is the best radiographic protocol for clinical trial of a structure modifying drug in patients with osteoarthritis. J Rheumatol. 2002;29:1308-1320.
19. Garnero P, Ayral X, Rousseau JC, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 2002;46(10):2613-2624.